# A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

> **NCT02932410** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 165 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Macitentan
- **OTHER:** Standard-of-care

## Key facts

- **NCT ID:** NCT02932410
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2024-08-28
- **Final completion:** 2025-11-27
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932410, "A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02932410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*